Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

[1]  B. Monk,et al.  Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Scambia,et al.  Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study. , 2016, Gynecologic oncology.

[3]  M. Parmar,et al.  Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[4]  A. Reuss,et al.  Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Monk,et al.  State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. , 2015, Gynecologic oncology.

[6]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[7]  T. Herzog,et al.  Emerging therapies: angiogenesis inhibitors for ovarian cancer , 2015, Expert opinion on emerging drugs.

[8]  B. Monk,et al.  Incorporation of pazopanib in maintenance therapy of ovarian cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Monk,et al.  Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.

[10]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Eisenhauer,et al.  Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer? , 2013, International Journal of Gynecologic Cancer.

[12]  B. Monk,et al.  Latest research and treatment of advanced-stage epithelial ovarian cancer , 2013, Nature Reviews Clinical Oncology.

[13]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[14]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[15]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  V. Gebski,et al.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Monk,et al.  Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds , 2009, International Journal of Gynecologic Cancer.

[18]  D. Levine,et al.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. , 2009, Gynecologic oncology.

[19]  A. Reuss,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[20]  D. Cella,et al.  Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Eisenhauer,et al.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Y. Hung,et al.  Vascular Endothelial Growth Factor-C Expression and Invasive Phenotype in Ovarian Carcinomas , 2005, Clinical Cancer Research.

[23]  D. Cella,et al.  Reliability and validity of the functional assessment of cancer therapy-ovarian. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  B. Karlan,et al.  Secondary surgical cytoreduction for advanced epithelial ovarian cancer: Patient selection and review of the literature , 1996, Cancer.

[26]  G. Martiny-Baron,et al.  Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates. , 1996, Clinical chemistry.

[27]  D L DeMets,et al.  Changing frequency of interim analysis in sequential monitoring. , 1989, Biometrics.

[28]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[29]  A. Reuss,et al.  Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. , 2016, The Lancet. Oncology.

[30]  V. Gebski,et al.  Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. , 2015, Gynecologic oncology.

[31]  Cancer Therapy Evaluation Program.  Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .

[32]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[33]  M. Piccart,et al.  Use of tumour markers in monitoring the course of ovarian cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  D.,et al.  Regression Models and Life-Tables , 2022 .